NCT02031744View on ClinicalTrials.gov

A Study of the Efficacy and Safety of MetMAb Combined With Tarceva in Patients With Met-Positive Non-Small Cell Lung Cancer

PHASE3CompletedINTERVENTIONAL
Enrollment

530

Participants

Timeline

Start Date

January 22, 2014

Primary Completion Date

January 6, 2016

Study Completion Date

January 6, 2016

Conditions
Non-Small Cell Lung Cancer
Interventions
DRUG

erlotinib [Tarceva]

150 mg oral administration once daily

DRUG

Placebo

15 mg/kg intravenous administration every 3 weeks

DRUG

Onartuzumab [MetMAb]

15 mg/kg intravenous administration every 3 weeks

Trial Locations (8)

100071

The Affiliated Hospital of Military Medical Sciences(The 307th Hospital of Chinese PLA), Beijing

130012

Jilin Cancer Hospital, Changchun

150081

Harbin Medical University Cancer Hospital, Harbin

210009

Jiangsu Cancer Hospital, Nanjing

310022

Zhejiang Cancer Hospital, Hangzhou

400038

Southwest Hospital , Third Military Medical University, Chongqing

400042

Third Affiliated Hospital of Third Military Medical University, Chongqing

510060

Sun Yet-sen University Cancer Center, Guangzhou

All Listed Sponsors
lead

Hoffmann-La Roche

INDUSTRY

NCT02031744 - A Study of the Efficacy and Safety of MetMAb Combined With Tarceva in Patients With Met-Positive Non-Small Cell Lung Cancer | Biotech Hunter | Biotech Hunter